Performance of the AmpliSeq NGS panel in thyroid nodules with indeterminate cytology.

ABSTRACT:

Objective

Fine-needle aspiration (FNA) cytological analysis fails to confirm the benignity or malignancy of Bethesda III, IV and V thyroid nodules. Molecular tests performed on FNA samples have demonstrated interesting results in improving the diagnosis of these nodules. The aim of this study was to assess the performance of a large next-generation sequencing (NGS) panel in thyroid nodules with indeterminate cytology (Bethesda III, IV and V).

Methods

Retrospective, monocentric study including 121 patients with cytologically indeterminate thyroid nodules (Bethesda III, IV and V) who underwent a routine FNA procedure for molecular testing using the AmpliSeq general cancer NGS panel, with an available final histological diagnosis. The main objective was to estimate the negative

SUBMITTER: Potonnier W 

PROVIDER: S-EPMC11816033 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature